Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
What's wrong with Raleigh tap water? Algae bloom at Falls Lake behind the smell, color
Recommended
Homeowners insurance doesn't cover floods: How to protect your home in North Carolina
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
70.85
+0.72 (+1.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Today 15:00 EDT
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.
Via
InvestorPlace
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Today 7:00 EDT
Why Quality-Oriented Investors Should Consider NASDAQ:AZN.
Via
Chartmill
European Stock: AstraZeneca
April 22, 2024
AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and...
Via
Talk Markets
Looking At AstraZeneca's Recent Unusual Options Activity
April 19, 2024
Via
Benzinga
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory...
Via
Benzinga
Topics
Brexit
Exposures
Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
April 19, 2024
These are the undervalued blue-chip stocks for inflation protection, with the Fed likely to delay the first interest rate cut.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
A Closer Look at AstraZeneca's Options Market Dynamics
April 03, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival...
Via
Benzinga
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 14, 2024
Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA...
Via
Benzinga
Exposures
Product Safety
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...
Via
Benzinga
Exposures
Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
April 07, 2024
This week's top stories highlight significant developments, including the U.S. manufacturing sector reaching an 18-month high, potential deflation from China's manufacturing growth, a robust U.S. labor...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
April 05, 2024
High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown...
Via
Benzinga
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over...
Via
Benzinga
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
March 28, 2024
These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
March 28, 2024
Invest in stability, dividends, and growth with these three accomplished real estate operators.
Via
The Motley Fool
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
March 27, 2024
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca...
Via
Benzinga
EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings
March 21, 2024
Dr. Laura Chico, Senior VP at Wedbush, is optimistic about 2024 biotech IPO market and M&A trends. Election year may affect performance.
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
March 21, 2024
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression.
Via
Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
March 21, 2024
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...
Via
Benzinga
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
March 20, 2024
These are the stagnating blue-chip stocks to buy at undervalued levels, as they represent fundamentally strong ideas with healthy cash flows.
Via
InvestorPlace
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
March 19, 2024
The company is working on radiopharmaceuticals treatments for cancer.
Via
Investor's Business Daily
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?
March 19, 2024
Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 19, 2024
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning!
Via
InvestorPlace
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.